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Passive immunization with antibodies to recombinant Plasmodium falciparum P0 riboprotein (rPfP0, 61–316 amino acids)
provides protection against malaria. Carboxy-terminal 16 amino acids of the protein (PfP0C0) are conserved and show 69%
identity to human and mouse P0. Antibodies to this domain are found in 10–15% of systemic lupus erythematosus patients. We
probedthenatureofhumoralresponsetoPfP0C0byrepeatedlyimmunizingmicewithrPfP0.Wefailedtoraisestableanti-PfP0C0
hybridomas from any of the 21 mice. The average serum anti-PfP0C0 titer remained low (5.1 ± 1.3 × 104). Pathological changes
were observed in the mice after seven boosts. Adsorption with dinitrophenyl hapten revealed that the anti-PfP0C0 response was
largely polyreactive. This polyreactivity was distributed across all isotypes. Similar polyreactive responses to PfP0 and PfP0C0 were
observed in sera from malaria patients. Our data suggests that PfP0 induces a deviant humoral response, and this may contribute
to immune evasion mechanisms of the parasite.
1.Introduction
Ribosomal phosphoprotein P0 is a highly conserved neutral
protein found in the 60S ribosomal subunit of eukaryotes
[1]. P0, along with the related acidic ribosomal phospho-
proteins P1 and P2, forms a pentameric protein complex
(P1)2-P0-(P2)2 thathasaroleintheassemblyoftheGTPase-
binding site in the large subunit of ribosomes [2–4]. P0
is vital to cell survival as knocking it out is lethal in Sac-
charomyces cerevisiae and Plasmodium berghei [5, 6]. It has
been postulated to have multiple other functions including
apurinic-apyrimidinic endonuclease activity in Drosophila
melanogaster [7],regulationofgeneexpressioninDrosophila,
and apoptosis and carcinogenesis in humans [7–10]. P0 has
been shown to be present on the surface of Plasmodium spp.,
Toxoplasma gondii,Saccharomycescerevisiae[11]aswellason
the surface of neuronal, hepatic, and other cell lines [12, 13].
Human P proteins have been studied extensively because of
their association with systemic lupus erythematosus (SLE),
an autoimmune disorder. Approximately, 10 to 15% of
patients suﬀering from SLE possess autoantibodies against
the conserved 16 carboxy-terminal amino acids [14]. Clustal
analysis reveals that this region of the protein is highly
conserved across diverse species [15]. Human and mouse P0,
forinstance,diﬀeronlyinsixaminoacidsandareidenticalin
the lupus domain (Figure 1). We have previously shown that
87% of adult residents in high-transmission malaria areas
of eastern India possessed antibodies against Plasmodium
falciparum P0 (PfP0) [16]. Similarly, 60% of adults residing
in Kenya showed substantial T-cell responses to PfP0 protein
[17]. Polyclonal and monoclonal antibodies against PfP0
have been shown to block parasite invasion of red blood cells2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic representation of PfP0, recombinant PfP0, and PfP0C0 and P0 multiple sequence alignment.
in vitro and in vivo [15, 18, 19]. When we attempted to raise
monoclonal antibodies (mAbs) against the major fragment
of PfP0, recombinant PfP0 (rPfP0, 61−316 amino acids), we
found that the ﬁrst mouse, receiving 7 injections (4 weekly,
3 monthly), gave rise to unstable hybridomas reacting to
the amino-terminus of the protein. The second mouse re-
ceiving 9 injections of the protein (4 weekly, 5 monthly),
gave rise to several independent mAb clones, most of them
reactingexclusivelytotheextremecarboxy-terminal,PfP0C0
(300−316 amino acids, Figure 1)[ 19]. The serum from
this mouse reacted exclusively with rPfP0 and PfP0C0, but
did not recognize other overlapping peptides derived from
the protein [20]. PfP0C0 shows 69% identity to carboxy-
terminal of human P0. This predominance of antibodies
towards the lupus domain could have been a result of the
age of the mouse (8 months), because of breakdown of
immune tolerance following repeated immunizations, or
both.Alternatively,itwaspossiblethatitwasanidiosyncratic
response of that mouse.
PfP0isapotentialvaccinecandidatesinceanti-PfP0anti-
bodies were shown to protect against malarial infection in
the murine model [18, 19]. Because of its conserved nature
and the homology of the carboxy-terminal domain to the
human protein, it is also likely to behave like an autoantigen.
It was important to ascertain the quality and quantity of hu-
moral response induced by the protein after repeated immu-
nizations. We therefore undertook this systematic study
w h e r e i nw ea t t e m p t e dt or a i s em A b sa g a i n s tP f P 0 C 0a f t e r
repeated immunizations with rPfP0. Selection processes in
the central and peripheral levels govern the survival of B cells
capable of responding to a particular immunogen, whereas
peripheral antigen-driven selection processes determine the
type and extent of humoral response. We reasoned that if
splenicBcellsareareﬂectionofthewholeBcellresponseand
that B cell speciﬁcity does not bias hybrid formation, then
thefrequencyofhybridomasformedshouldreﬂectimmuno-
genicityofdiﬀerentepitopesofPfP0.Wealsoinvestigatedthe
nature of the serum anti-PfP0C0 response.
We failed to raise a single anti-PfP0C0 hybridoma from
any of the 21 mice used in these subsequent experiments,
suggesting thatthe ﬁrst successin raising hybridomas against
thePfP0C0domainwasprobablyduetoanunusualresponse
observed in that one single mouse (of combined 23 mice
used in the two studies). We observed connective tissue
ﬁbrosis of the spleen from the fourth month of the immu-
nization schedule, and this increased progressively with fur-
ther immunizations. Postmortem examination revealed
pathological changes in the liver, heart, kidneys, and lungs of
the mice. The average serum anti-PfP0C0 titre remained low
(5.1±1.3×104) evenafter10boosters. Dinitrophenyl (DNP)
adsorption studies revealed that the humoral response was
largely polyreactive. This polyreactivity was not conﬁned to
any particular immunoglobulin isotype, but was distributed
acrossallisotypes.Sequenceanalysisofthesevenhybridomas
obtained in the initial study revealed that they were derived
from a single clone. We analysed sera from uncomplicated
malaria patients to determine the extent of polyreactivity
to the protein. Our analysis revealed a similar polyreactive
response to PfP0 and the PfP0C0 epitope in these sera.
Our data suggests that PfP0 induces a deviant humoral
response in mice. Induction of deviant, low-titre, polyreac-
tive responses is likely a method of evading the host immune
system.
2.MaterialsandMethods
2.1. Mice. Six-week-old female Balb/c mice were obtained
from the local animal breeding facility at the Tata Institute
of Fundamental Research, Mumbai, India. Mice were bred
and maintained under speciﬁc pathogen-free conditions. All
experimental research was conducted according to recom-
mendations of the CPCSEA (Committee for the Purpose of
Control and Supervision on Experiments on Animals).
2.2. Immunizations and Establishment of Hybridomas. Im-
munogens and peptides: the expression and puriﬁcation ofJournal of Biomedicine and Biotechnology 3
recombinant PfP0 (amino acids 61−316) as a GST fusion
protein was done as described earlier [21]. The recombinant
E. coli cells containing PfP0 gene fragment were grown
f o r2 ha t3 7 ◦C, induced with IPTG, harvested, and lysed.
The cell lysates were centrifuged, and insoluble particulate
fraction containing the fusion protein was resolved on SDS-
polyacrylamide preparative gel. A strip of the gel corre-
sponding to MW of the recombinant protein was excised,
electroeluted, dialysed against PBS, and concentrated. The
identity of the protein was conﬁrmed by Western blot analy-
sis as described [22]. Ant brain homogenate, P. falciparum
phosphofructokinase, P. falciparum enolase were prepared
as described [23–25]. P0 protein from Toxoplasma gondii
(TgP0) was cloned in pGEX4T1 and expressed as a GST
fusion protein. The recombinant, full-length GST−TgP0was
extracted from induced cell pellets using sarkosyl [26], puri-
ﬁed from the lysate using Glutathione sepharose beads (GE
Healthcare), washed thrice with PBS containing 150mM
NaCl, and eluted using 100mM glutathione. The identity of
the protein was conﬁrmed using SDS-PAGE and Western
blotting (data not shown) Bovine serum albumin coupled
to PfP0C0 (BSA-PfP0C0) was prepared as described earlier
[19].
ThesyntheticpeptidesMoP0C0(EESEESDEDMGFGLF-
D), PfP0C0 (EEEEEEDGFMGFGMFD) were obtained from
Mimotopes,Canberra,Australia.Bovineinsulin,ssDNA,and
dsDNA were obtained from Sigma (St Louis, MO, USA).
Immunization and hybridoma establishment was done
as described by Rajeshwari et al., 2004 [19]. Brieﬂy, 50μgs
of protein emulsiﬁed in Freund’s adjuvant was administered
intraperitoneally in mice. The animals received four weekly
injectionsfollowedbymonthlyinjections.Exceptfortheﬁrst
immunization where Freund’s complete adjuvant was used,
the rest of the immunizations employed Freund’s incomplete
adjuvant. 4 days before fusion, the mice were boosted with
250μg of the immunogen in saline. Mice were sacriﬁced
after each monthly injection, their serum was collected,
their spleens were harvested, and the splenocytes were fused
with the mouse myeloma Sp2/0 cells. Antibody-secreting
cloneswereselectedbyELISA[27].Immunogen-recognizing
hybridomas were subcloned to monoclonality by limiting
dilution. For rPfP0 immunizations, mice were given up to
seven monthly immunizations; three mice were sacriﬁced
after each monthly immunization.
2.3. Human Serum Samples. Serum samples were collected
from patients of uncomplicated malaria as well as immune
adults living in high endemicity area in Orissa, India. Pre-
sence or absence of P. falciparum infection was conﬁrmed
by microscopic examination of Giemsa-stained thick and
thin blood smears or by using commercial kits. The samples
were collectedafter informed consent and after obtaining the
requisiteclearancesfromtheEthicsCommittee,SCBMedical
College and Hospital, Cuttack, India.
2.4. ELISA. Antibody response was determined by ELISA
[19]. Brieﬂy, Maxisorp plates (Nunc, Roskilde, Denmark)
were coated overnight at 4◦C with whole antigens (5μg/mL)
or synthetic peptides (200ng/mL) in PBS, pH 7.2. The
plates were blocked with 1% BSA before adding hybridoma
supernatants or appropriate dilutions of the serum, devel-
oped using rabbit anti-mouse Ig conjugated to horseradish
peroxidase (Boehringer Mannheim, Mannheim, Germany)
and ABTS (Boehringer Mannheim), and the absorbance
(optical density; OD) was measured at 405nm with EL808
Ultra Microplate reader (Biotek Instruments Inc, Winooski,
VT, USA).
To detect polyreactivity, DNP was conjugated to CNBr-
activated sepharose beads (GE Healthcare, Little Chalfont,
Buckinghamshire, UK) as per manufacturer’s instructions.
Brieﬂy, 2,4-DNP-ε-lysine (Sigma) was dissolved in 0.1M
NaHCO3 pH 8.3 containing 0.5M NaCl, added to sepharose
beads swollen in 1mM HCl, and incubated on an end-
over-end mixer for 1h at room temperature. After washing
away the excess ligand, the active sites were blocked using
0.1M Tris-HCl buﬀer, pH 8.0. The beads were washed
with three cycles of 0.1M acetic acid/sodium acetate, pH
4.0 containing 0.5M NaCl followed by a wash with 0.1M
Tris-HCl, pH 8 containing 0.5M NaCl. Aliquots of serum
dilutions were incubated or not with DNP-sepharose beads
for 1.5 hour on a nutator and centrifuged. The supernatant
was diluted further for use in ELISA. Percent polyreactivity
was calculated as under:
%p o l y r e a c t i v i t y
=
OD of unadsorbed serum−OD of adsorbed serum
OD of unadsorbed serum
×100.
(1)
2.5. Determination of RNA Sequence of Anti-PfP0C0 mAb
Clones. Anti-PfP0C0 antibody producing hybridoma clones
(1A4, 1B3, 2C11, 1E5F4, 1F6, 2G1, and 2H1) were lysed in
Trizol (Invitrogen, Carlsbad, CA, USA), and RNA was pre-
pared according to manufacturer’s protocol. cDNA was pre-
pared from the RNA using 3  primer (heavy or light chain
constant primer) and MMLV reverse transcriptase (NEB).
PCRampliﬁcationsoflightandheavychainswereperformed
using primers described in Table 1. Conditions used to am-
plify PCR fragments were as follows: DNA melting at 91◦C
for 1min, primer annealing 52◦Cf o r2m i n ,a n dp o l y m e r a s e
extension at 72◦C for 1.5min for 30 cycles were carried out.
The PCR products were TA cloned in pGEM-T vector system
(Promega, Madison, WI, USA), and ligation mixes were used
to transform XL-1 Blue E. coli bacteria. Positive clones were
sequenced using M13F (5 d [GTAAAACGACGGCCAG]3 )
and M13R (5 d [CAGGAAACAGCTATGAC]3 )p r i m e r s .
2.6. Statistical Analysis. Paired Wilcoxan signed-rank test
was used to compare and evaluate the statistical signiﬁcance
of the unadsorbed and adsorbed OD of mouse sera. Non-
parametric Mann-Whitney test was used to evaluate the sta-
tistical signiﬁcance of the human serum data. GraphPad
Instat software was used for analysis.
3. Results and Discussion
3.1. Recombinant PfP0 Immunizations Failed to Yield Sta-
ble Anti-PfP0C0 mAb Producing Hybridomas. We were4 Journal of Biomedicine and Biotechnology
Table 1: Primers used to amplify antibody variable regions.
Heavy chain 3  primer
IgG1 5  AGG CTT ACT AGT ACA ATC CCT GGG CAC AAT 3 
Heavy chain 5  primers
HC1 5  AGG TCC AGC TGC TCG AGT CTG 3 
HC2 5  AGG TCC AGC TGC TCG AGT CAG 3 
HC3 5  AGG TCC AGC TTC TCG AGT CTG 3 
HC4 5  AGG TCC AGC TTC TCG AGT CAG 3 
HC5 5  AGG TCC AAC TGC TCG AGT CTG 3 
HC6 5  AGG TCC AAC TGC TCG AGT CAG 3 
HC7 5  AGG TCC AAC TTC TCG AGT CTG 3 
HC8 5  AGG TCC AAC TTC TCG AGT CAG 3 
Kappa light chain 3  primer
MKC 5  GCG CCG TCT AGA ATT AAC ACT CAT TCC TGT TGA A 3 
Kappa light chain 5  primers
LC1 5  CCA GTT CCG AGC TCG TTG TGA CTC AGG AAT CT 3 
LC2 5  CCA GTT CCG AGC TCG TGT TGA CGC AGC CGC CC 3 
LC3 5  CCA GTT CCG AGC TCG TGC TCA CCC AGT CTC CA 3 
LC4 5  CCA GTT CCG AGC TCC AGA TGA CCC AGT CTC CA 3 
LC5 5  CCA GAT GTG AGC TCG TGA TGA CCC AGA CTC CA 3 
LC6 5  CCA GAT GTG AGC TCG TCA TGA CCC AGT CTC CA 3 
LC7 5  CCA GTT CCG AGC TCG TGA TGA CAC AGT CTC CA 3 
interested in raising mAbs against the recombinant P. falci-
parum ribosomal protein P0 (PfP0) as polyclonal antibodies
to this protein had inhibited parasite invasion of red blood
cells [15, 19]. In a previous study, we were successful in rais-
ing stable mAbs against PfP0 after multiple immunizations
only in one mouse, and most of these were against PfP0C0
[19]. Since the extreme C-terminal domain of human P0
protein is homologous to PfP0 carboxy-terminus (PfP0C0;
300−316 amino acids) and is the major P-protein autoanti-
gen involved in lupus [14], we were interested in probing the
nature of the humoral response to PfP0C0 and wanted to
determine the frequency with which we would obtain mAbs
against this domain of PfP0 protein. The full-length protein
shows extremely poor expression, hence we used the major
fragment of the protein (rPfP0, 61−316 amino acids) for
immunizations.
We immunized 6-week-old Balb/c mice with four weekly
injections of rPfP0 in Freund’s complete adjuvant, followed
by monthly boosters. Spleens from 3 mice each were har-
vestedaftereachmonthlyinjection(5ththrough11thimmu-
nization) for hybridoma preparation. Table 2, shows the
results for 5th, 7th, 9th, and 11th immunization. Similar
results were obtained for the remaining time points. As is
seen from Table 2, we failed to obtain any stable clones
against PfP0C0, despite repeated immunizations or the age
of the mice. Screening of about 1800 clones yielded only
22 stable clones. Most clones were either polyreactive or
stopped antibody production within a few days and failed
to recognize the carboxy-terminal epitope. Thus, neither age
of the animal nor repeated immunizations with a potential
autoantigen could be the reason for the success of raising
hybridomas in the initial study.
Our failure to raise stable hybridomas against PfP0C0
cannot be attributed to faulty technique, since we succeeded
in obtaining multiple stable clones against a variety of pro-
teins (Table 2). These include ant brain homogenate,
Drosophila translin which bears 52% homology with the
mouse protein [28], parasite proteins such as P. falciparum
fructokinase-β, and potential autoantigenic proteins such as
P. falciparum enolase [29, 30] and TgP0. The identity of
PfP0 and mouse P0 C-terminus over the extreme 16 amino
acids is 69% (Figure 1). This homology of PfP0 to mouse
P0 alone cannot be the only reason for lack of hybridomas,
since both P. falciparum enolase and TgP0 show considerable
homologies with mouse enolase and mouse P0 (75% and
62.5%, resp.), and these were amenable to generation of
a large number of stable hybridomas. Secondary antigenic
challenges result in the generation of long-lived plasma
cells capable of secreting high-aﬃnity antibodies to the
immunizing antigen [31]. It is tempting to speculate that
PfP0 is an unusual antigen in that it failed to induce a robust
B cell response, since repeated immunizations yielded very
few stable hybridomas, and none of them were against the
immunogenic carboxy-terminus of the antigen.
3.2. Earlier mAbs Raised against PfP0C0 Arose from a Single
B Cell Clone. Since in our previous studies we obtained
severalmAbsexclusivelyagainstPfP0C0fromonemouse,we
analyzed the isotype and sequences of the seven mabs (1A4,
1B3,2C11,1E5F4,1F6,2G1,and2H1)fromthisearlierstudy
to establish their relatedness, if any. Isotype analysis showed
that all the mAbs belonged to IgG1 isotype. We performed
RT-PCRs and ampliﬁed products of the heavy and the light
chains of these seven mAb clones and sequenced themJournal of Biomedicine and Biotechnology 5
Table 2: Serum titre and hybridomas obtained following repeated immunizations with various proteins.
Immunization
number
Number of mice screened Number of clones screened Stable clones (speciﬁcity) Serum titre (×104) Splenic ﬁbrosis
Recombinant PfP0
4 16 ND − 2.5 ±0.6 −
5 2 120 0 ND −
7 3 282 0 2.4 ±0.1+
9 3 478 9 (Mouse P0, polyreactive) 5.3 ±1.3+ +
11 2 571 13 (non-PfP0C0, GST) 4.0 ±1.0 +++
Ant-brain homogenate
4 1 700 33 5 −
Drosophila Translin
3 1 290 22 >10 −
Plasmodium falciparum Phosphofructokinase
3 1 190 7 >50 −
Plasmodium falciparum enolase
5 1 290 10 >50 −
Toxoplasma gondii P0
5 1 300 >70 >17 −
ND: not done; −: negative, +: mild, ++: moderate, +++: severe.
Table 3: Results of histopathological investigations of mice following repeated recombinant PfP0 administrations.
Organ Severity Changes observed
Liver +++ Severe swelling and derangement of cords, inﬁltration of mononuclear cells around the portal triad
Kidneys +++ Tubular necrosis and diﬀuse necrotic changes along with inﬁltration of inﬂammatory cells around the necrotic area
Lungs +++ Edema, congestion, MNC inﬁltration, diﬀuse interstitial and patchy pneumonia
Heart + Mild congestion and swelling of ﬁbres
Spleen +++ Loss of lymphoid cells, replaced by connective tissue
Brain − No abnormality detected
−: negative, +: mild, +++: severe.
(Figure 2). It was observed that the CDR2 and CDR3 regions
were identical for the heavy chain in all seven clones. Two
single base changes in CDR1 region of 1A4 and 1E5F4 and 3
base changes in 2C11 gave rise to some amino acid changes
in the CDR1 region of 3 out of 7 clones. Regarding the
light chain, 1A4 and 2C11 showed certain base changes,
while all the other ﬁve clones were identical. Although the
CDR3 region of 1A4 was decidedly diﬀerent, the CDR1 and
2 regions were near identical. The remaining regions of the
IgG1 chains of these clones were identical (data not shown).
It is therefore apparent that the clones obtained in the earlier
study originated from a single B cell clone. This could be due
to an unusual expansion of the clone, possibly due to break-
down of tolerance, and was deﬁnitely an aberrant incidence
since subsequent analysis failed to reproduce our earlier
result of obtaining mAb clones against PfP0C0 (Table 2).
3.3.RecombinantPfP0ImmunizationsResultedinPathological
Changes in the Mice. During the course of spleen harvesting
for hybridoma generation, we noticed mild connective tissue
ﬁbrosis of the spleen from the 7th immunization (Table 2).
The animals started to become sick following the booster
immunization. This ﬁbrosis worsened progressively, and by
11th immunization the spleen became diﬃcult to harvest
(Figure 3). Marked splenic ﬁbrosis had not been observed in
the earlier study. Since the aim of that study was to obtain
mAbs to PfP0C0, postmortem pathological examination had
also not been undertaken. Postmortem analysis of the mice
revealed pathological changes in all the major organs such
as the heart, lungs, liver, and kidneys (Table 3). Interestingly,
no abnormality was detected in the brain. These ﬁndings
suggested that repeated immunizations with rPfP0 resulted
in a humoral autoimmune response, possibly because of
the homology between the parasite P0 and mouse P0. The
brain is well separated from blood by the blood-brain bar-
rier. Antibodies do not normally cross this barrier [32].
The pathological changes observed in all the major organs
excluding the brain suggested autoantibodies as a possible
cause of the damage. We therefore investigated the serum Ig
response to PfP0C0.
3.4. Recombinant PfP0 Induces a Low-Titre, Largely Polyre-
active Serum Anti-PfP0C0 Response. Sera collected from the
mice after each monthly immunization with rPfP0 were test-
ed for their anti-PfP0C0 response. The serum titre remain-
ed low even after the 11th administration of the protein6 Journal of Biomedicine and Biotechnology
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Figure 2: Sequence determination of anti-PfP0C0 mAbs obtained in the ﬁrst study. Seven mAbs obtained in our earlier study [19], namely,
1A4, 1B3, 2C11, 1E5F4, 1F6, 2G1 and 2H1 were sequenced to determine their relatedness. Except for some minor variations (in red), all
seven mAbs were nearly identical, suggesting that they had arisen from a single B cell clone.Journal of Biomedicine and Biotechnology 7
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Figure 3: Splenic ﬁbrosis observed after repeated immunizations with recombinant PfP0. (a) Spleen of control mice. (b) Spleen of a mouse
following repeated immunization with recombinant PfP0 (four weekly and seven monthly). Arrows point to the spleen. Note the reduced
size of the spleen and ﬁbrosis around it. Histopathological analysis revealed a loss of lymphoid cells and extensive replacement of splenic
tissue with connective tissue.
(Table 2). By contrast, high-titre responses were obtained
after just 4 or 5 immunizations against a variety of other
proteins, including those that displayed a high degree of
homology to mouse proteins such as P. falciparum enolase,
Drosophila translin, and TgP0. The low titre of the sera,
coupled with the unstable polyreactive hybridomas ob-
tained, suggested the possibility that the induced anti-
PfP0C0 response was polyreactive. Polyreactive antibodies
are low aﬃnity antibodies that can bind a range of biological
molecules of both self- and non-self-origin [33, 34]. They
are normal serum constituents and are a signiﬁcant part of
the initial immune response. DNP treatment is commonly
used to remove polyreactive antibodies in animals not ex-
posed to the hapten [35, 36]. We treated the sera with DNP-
sepharose beads and determined the anti-PfP0C0 titre of
adsorbed and unadsorbed sera in ELISA. Treatment with
DNP led to a statistically signiﬁcant reduction in the anti-
PfP0C0 reactivity of the sera, indicating that PfP0 immuni-
zation induced a largely polyreactive anti-PfP0C0 response.
Figure 4(a) shows a typical response of DNP adsorbed and
unadsorbed serum sample. The extent of polyreactivity re-
mained high (median value 32%) even after repeated boost-
ers (Figure 4(b)). This polyreactive response was not con-
ﬁned to a particular isotype, but was found across all
isotypes, since DNP treatment resulted in statistically sig-
niﬁcant reduction in anti-PfP0C0 response in all isotypes
(Figure 4(c)). We also tested the sera for reactivity against
dsDNA,ssDNA,andinsulin.Figure 4(d)showstheresultofa
single serum sample. Similar results were obtained for other
samples (data not shown).
3.5. Malarial Infection Also Results in a Low-Titre, Largely
Polyreactive Serum Anti-PfP0 and Anti-PfP0C0 Response. We
wished to determine if serum from patients of uncompli-
cated malaria also showed a similar polyreactive response to
PfP0. The protein is highly conserved across P. falciparum.
Amongst the 13 strains reported in PlasmoDB [37], the
DNA sequence is identical except for a single synonymous
mutation in one strain (Figure 5). PfP0 is also abundantly
expressed on the surface of merozoites [18]. Although we
normally see elevated antibody responses to PfP0 in mala-
ria immune adults as compared to patients [18], we had
not assessed the polyreactive component earlier. We tested
sera from immune adults as also patients of uncompli-
cated malaria for anti-PfP0 and anti-PfP0C0 antibodies. In
agreement with our earlier results, immune adults, but not
patients, showed an elevated response to PfP0 (Figure 6(a),
P<0.01). Analysis of the response for polyreactivity to
PfP0 revealed that the patient’s sera were highly polyreactive
(Figure 6(b); median value 44.8%). By contrast, sera from
immune adults exhibited minimal polyreactivity to the pro-
tein (P = 0.001; median value 13.9%). Similar results were
obtained for PfP0C0 (data not shown).
Polyreactive autoantibodies have been reported in Plas-
modium-chabaudi-infected mice [38]. The autoantibodies
found in clinically protected persons resident in malaria
hyperendemic areas are similar to those present in disorders
such as SLE, rheumatoid arthritis, Sjogren’s syndrome, poly-
myositis, scleroderma, and Hashimoto’s thyroiditis. These
can bind to double- and single-stranded DNA, erythrocytes,
immunoglobulins, ribonucleoproteins, and enolase. How-
ever, anti-thyroglobulin antibodies, autoreactive to B cells
and found in normal persons, are not enhanced in such a
population, indicating that it is not a matter of random non-
speciﬁc polyclonal B cell activation against conserved anti-
gens [18, 25, 39, 40]. It is unlikely that homology of
PfP0 to the host protein is responsible for the observed
polyreactive response since repeated immunizations with
Pf enolase or bovine serum albumin coupled to PfP0C0
(BSA-PfP0C0)failedtoinduceapolyreactiveresponse.Inter-
estingly, although speciﬁc, BSA-PfP0C0 administration did
not induce a high titre anti-PfP0C0 response (titre ∼2×104,8 Journal of Biomedicine and Biotechnology
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Figure 4: Polyreactive serum anti-PfP0C0 response induced following repeated immunizations with rPfP0 but not BSA-PfP0C0. (a) Sera
of mice administered recombinant PfP0 were treated or not with DNP-sepharose beads. Anti-PfP0C0 titre before and after treatment was
determined in an ELISA. A representative example of anti-PfP0C0 response of DNP adsorbed (empty circles) and unadsorbed (ﬁlled circles)
sera. Error bars represent the SEM of three readings. (b) Mice were immunized by four weekly and up to seven monthly injections of
rPfP0. Aliquots of the sera were treated with DNP-sepharose beads to adsorb out polyreactive antibodies. The bar graphs depict the percent
polyreactivity in sera of mice after multiple immunizations as indicated. Error bars represent the SEM of 3 sera. (c) Box plots showing
the 25th and 75th percentiles, together with the median, with whiskers showing the minimum and maximum diﬀerence and ﬁlled circles
representing the outliers, in the ELISA OD responses of DNP unadsorbed (U) and adsorbed (A) sera of all 21 mice immunized with
recombinant PfP0; μ (IgM), γ1( I g G 1 )γ2a (IgG2a), γ2b (IgG2b), γ3 (IgG3), and α (IgA). Statistically signiﬁcant values obtained by Paired
Wilcoxan signed-rank test are indicated. (d) Autoreactivity of a representative serum sample against bovine insulin (closed circle), dsDNA
(open circle), and ssDNA (closed triangle) of mice immunized with rPfP0. Red line represents the response of control unimmunized sera at
the lowest dilution (1:1000). Error bars represent the SEM of three readings. Similar results were obtained with other sera. (e) Mice were
administered BSA-PfP0C0, and the sera were treated or not with DNP-sepharose beads. Anti-PfP0C0 titre before and after treatment was
determined in ELISA. A representative example of anti-PfP0C0 response of DNP adsorbed (empty circles) and unadsorbed (ﬁlled circles)
sera. Error bars represent the SEM of three readings.Journal of Biomedicine and Biotechnology 9
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Figure 6: Polyreactive serum anti-PfP0C0 response observed in uncomplicated malaria patients, but not in immune adults living in high
endemicity areas. (a) Box plots showing the 25th and 75th percentiles, together with the median, with whiskers showing the minimum
and maximum diﬀerence and ﬁlled circles representing the outliers in anti-PfP0 responses of sera from patients of uncomplicated malaria
(n = 49) and immune adults (n = 30) as determined in ELISA. (b) Box plots showing the 25th and 75th percentiles, together with the
median, with whiskers showing the minimum and maximum diﬀerence and ﬁlled circles representing the outliers of % polyreactivity in
anti-PfP0 responses of sera from patients and immune adults. The sera were treated or not with DNP-sepharose beads, and anti-PfP0 titre
before and after treatment was determined in ELISA to determine the % polyreactivity.
Figure 4(e)). However, this response was autoreactive, since
theserawerereactivetomouseP0C0,albeitatatenfoldlower
concentration (titre ∼2 ×103, data not shown). Thus, the
potentially autoreactive epitope coupled to a carrier protein
failed to induce a polyreactive response, but the recombinant
protein containing 61–316 amino acids induced a low-titre,
polyreactive response. This suggests that the capacity to
induce polyreactivity probably lies in the 61−300 region of
the protein. It is also possible that the conformation of the
protein is an important factor in the induction of poly-
reactivity or that rPfP0 acts like a B cell mitogen. Further
investigations are needed to determine if a particular region
and/or the conformational structure of the protein is res-
ponsible for induction of a polyreactive response.
Normal human serum contains natural autoantibod-
ies that recognize self-antigens [41]. Analysis of human
monoclonal autoantibodies derived from normal peripheral
blood B cells has shown that natural autoantibodies are
polyreactive and express germline immunoglobulin variable
region genes with little or no somatic mutation [42, 43],
although polyreactivity has also been observed in aﬃnity-
matured antibodies [44]. The capacity to adopt multiple
conformational states in equilibrium allows polyreactive
antibodies to bind multiple, structurally unrelated antigens
[45]. Polyreactive antibodies have been reported to be
induced in murine model of malaria [38]. We show that
immunization with a parasite-derived protein can also in-
duce a polyreactive response. Interestingly, we ﬁnd people
suﬀering from malaria also exhibit a polyreactive response
to PfP0. This polyreactive response was conﬁned to patients,
since sera from immune adults showed a comparatively non-
polyreactive response to the protein. We have earlier shown10 Journal of Biomedicine and Biotechnology
that PfP0 is expressed on the surface of merozoites [18].
Thus, it could be that exposure to low levels of the protein
(as would happen in the case of immune endemic adults)
results in speciﬁc response to the protein, and this speciﬁc
response protects against malarial disease. Exposure to high
doses of the protein (e.g., during active malarial disease or
duringimmunizationprotocols),ontheotherhand,possibly
results in a polyreactive response. Further investigations are
needed to see if low doses of PfP0 with or without a strong
adjuvant result in a speciﬁc anti-PfP0 response.
Antibodies have a crucial role in the control of malarial
infection. Opsonization by antibodies to parasite proteins
expressed on the surface of merozoites or infected erythro-
cytes facilitates their removal and eventual destruction by
macrophages [46]. The malarial parasite has been shown
to subvert the host immune system in multiple ways in-
cluding antigenic variation and antigenic polymorphisms,
interference with dendritic cell maturation, and induction of
apoptosis in memory B and T cells [47–50]. Here, we show
that a conserved, parasite-derived protein induces a deviant
humoral response in the host. A propensity to express or
secrete conserved antigens that induce a weak polyreactive
humoral response could be one more mechanism of enhanc-
ing parasite survival.
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